cft

CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).

Tagarafdeg (CFT1946) is an orally available PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (type III) mutations, and the p61-BRAF V600E splice variant. It exhibits favourable selectivity within the proteome, including for wild-type BRAF and CRAF, and inhibits tumour cell proliferation.

CFT-2718 is an advanced BRD4-targeting PROTAC (proteolysis-targeting chimera) known for its improved catalytic efficiency and superior in vivo characteristics.

CFT-1297 is a BET PROTAC degrader that targets BRD4 for degradation.

CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome.

(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferation [1].

PROTAC BRD4 ligand-2 is a ligand for the target BRD4 protein used in the development of PROTAC CFT-2718.

PROTAC BRD4 Ligand-2 Hydrochloride serves as a ligand targeting the BRD4 protein, specifically designed for use with PROTAC CFT-2718.